OF OUR PAYLOAD
Merlin is developing novel approaches to diseases where there are few effective therapies. Our lead asset, MER-101 is a first-in-class immuno-oncology therapy being developed soley by Merlin for adult solid cancers and the rare pediatric cancer Ewing sarcoma. MER-201 and -202 are therapies against Lyme disease and chronic hepatitis B being developed through our partnerships with West Virginia University and the Baruch S. Blumberg Institute.
- Pediatric Ewing Sarcoma
- Adult Solid Tumors
Chronic Hepatitis B
Development partner: Baruch S. Blumberg
Development partner: West Virginia